Wall Street’s Most Accurate Analysts’ Views On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on¬†their favorite stocks¬†by visiting our¬†Analyst Stock Ratings¬†page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy .

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Johnson & Johnson (NYSE:JNJ)

  • Dividend Yield: 3.06%
  • Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $170 to $169 on Jan. 24, 2024. This analyst has an accuracy rate of 67%.
  • Raymond James analyst Jayson Bedford maintained an Outperform rating and boosted the price target from $172 to $175 on Jan. 3, 2024. This analyst has an accuracy rate of 67%.
  • Recent News: Johnson & Johnson is reportedly in talks to acquire Shockwave Medical, Inc (NASDAQ:SWAV).

Patterson Companies, Inc. (NASDAQ:PDCO)

  • Dividend Yield: 3.85%
  • Morgan Stanley analyst Erin Wright maintained an Equal-Weight rating and cut the price target from $38 to $35 on Nov. 30, 2023. This analyst has an accuracy rate of 77%.
  • Stifel analyst Jonathan Block reiterated a Hold rating with a price target of $32 on Nov. 28, 2023. This analyst has an accuracy rate of 77%.
  • Recent News: On March 11, Patterson Companies approved a $500 million stock buyback and declared a quarterly dividend of 26 cents per share.

Gilead Sciences, Inc. (NASDAQ:GILD)

  • Dividend Yield: 4.25%
  • Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and cut the price target from $84 to $77 on March 4, 2024. This analyst has an accuracy rate of 76%.
  • RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and lowered the price target from $76 to $75 on Feb. 14, 2024. This analyst has an accuracy rate of 71%.
  • Recent News: On March 22, Gilead Sciences announced completion of acquisition of CymaBay.

 

Read More: GameStop Posts Downbeat Results, Joins Direct Digital, Forge Global And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session



More Sponsored Headlines